These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 23089045)

  • 1. Developmental consequences of the ColQ/MuSK interactions.
    Karmouch J; Dobbertin A; Sigoillot S; Legay C
    Chem Biol Interact; 2013 Mar; 203(1):287-91. PubMed ID: 23089045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in the C-terminal domain of ColQ in endplate acetylcholinesterase deficiency compromise ColQ-MuSK interaction.
    Nakata T; Ito M; Azuma Y; Otsuka K; Noguchi Y; Komaki H; Okumura A; Shiraishi K; Masuda A; Natsume J; Kojima S; Ohno K
    Hum Mutat; 2013 Jul; 34(7):997-1004. PubMed ID: 23553736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Collagen Q and anti-MuSK autoantibody competitively suppress agrin/LRP4/MuSK signaling.
    Otsuka K; Ito M; Ohkawara B; Masuda A; Kawakami Y; Sahashi K; Nishida H; Mabuchi N; Takano A; Engel AG; Ohno K
    Sci Rep; 2015 Sep; 5():13928. PubMed ID: 26355076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific binding of collagen Q to the neuromuscular junction is exploited to cure congenital myasthenia and to explore bases of myasthenia gravis.
    Ohno K; Ito M; Kawakami Y; Krejci E; Engel AG
    Chem Biol Interact; 2013 Mar; 203(1):335-40. PubMed ID: 22981737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MuSK is required for anchoring acetylcholinesterase at the neuromuscular junction.
    Cartaud A; Strochlic L; Guerra M; Blanchard B; Lambergeon M; Krejci E; Cartaud J; Legay C
    J Cell Biol; 2004 May; 165(4):505-15. PubMed ID: 15159418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The collagen ColQ binds to LRP4 and regulates the activation of the Muscle-Specific Kinase-LRP4 receptor complex by agrin at the neuromuscular junction.
    Uyen Dao TM; Barbeau S; Messéant J; Della-Gaspera B; Bouceba T; Semprez F; Legay C; Dobbertin A
    J Biol Chem; 2023 Aug; 299(8):104962. PubMed ID: 37356721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuromuscular junction immaturity and muscle atrophy are hallmarks of the ColQ-deficient mouse, a model of congenital myasthenic syndrome with acetylcholinesterase deficiency.
    Sigoillot SM; Bourgeois F; Karmouch J; Molgó J; Dobbertin A; Chevalier C; Houlgatte R; Léger J; Legay C
    FASEB J; 2016 Jun; 30(6):2382-99. PubMed ID: 26993635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COOH-terminal collagen Q (COLQ) mutants causing human deficiency of endplate acetylcholinesterase impair the interaction of ColQ with proteins of the basal lamina.
    Arredondo J; Lara M; Ng F; Gochez DA; Lee DC; Logia SP; Nguyen J; Maselli RA
    Hum Genet; 2014 May; 133(5):599-616. PubMed ID: 24281389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Congenital myasthenic syndromes with acetylcholinesterase deficiency, the pathophysiological mechanisms.
    Legay C
    Ann N Y Acad Sci; 2018 Feb; 1413(1):104-110. PubMed ID: 29405353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ColQ controls postsynaptic differentiation at the neuromuscular junction.
    Sigoillot SM; Bourgeois F; Lambergeon M; Strochlic L; Legay C
    J Neurosci; 2010 Jan; 30(1):13-23. PubMed ID: 20053883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roles of collagen Q in MuSK antibody-positive myasthenia gravis.
    Ohno K; Otsuka K; Ito M
    Chem Biol Interact; 2016 Nov; 259(Pt B):266-270. PubMed ID: 27119269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Collagen Q is a key player for developing rational therapy for congenital myasthenia and for dissecting the mechanisms of anti-MuSK myasthenia gravis.
    Ohno K; Ito M; Kawakami Y; Ohtsuka K
    J Mol Neurosci; 2014 Jul; 53(3):359-61. PubMed ID: 24234034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholinesterases and the basal lamina at vertebrate neuromuscular junctions.
    Massoulié J; Millard CB
    Curr Opin Pharmacol; 2009 Jun; 9(3):316-25. PubMed ID: 19423392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synaptic basal lamina-associated congenital myasthenic syndromes.
    Maselli RA; Arredondo J; Ferns MJ; Wollmann RL
    Ann N Y Acad Sci; 2012 Dec; 1275():36-48. PubMed ID: 23278576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The synaptic muscle-specific kinase (MuSK) complex: new partners, new functions.
    Strochlic L; Cartaud A; Cartaud J
    Bioessays; 2005 Nov; 27(11):1129-35. PubMed ID: 16237673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-MuSK autoantibodies block binding of collagen Q to MuSK.
    Kawakami Y; Ito M; Hirayama M; Sahashi K; Ohkawara B; Masuda A; Nishida H; Mabuchi N; Engel AG; Ohno K
    Neurology; 2011 Nov; 77(20):1819-26. PubMed ID: 22013178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein-anchoring therapy to target extracellular matrix proteins to their physiological destinations.
    Ito M; Ohno K
    Matrix Biol; 2018 Aug; 68-69():628-636. PubMed ID: 29475025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein-anchoring strategy for delivering acetylcholinesterase to the neuromuscular junction.
    Ito M; Suzuki Y; Okada T; Fukudome T; Yoshimura T; Masuda A; Takeda S; Krejci E; Ohno K
    Mol Ther; 2012 Jul; 20(7):1384-92. PubMed ID: 22371845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The MuSK activator agrin has a separate role essential for postnatal maintenance of neuromuscular synapses.
    Tezuka T; Inoue A; Hoshi T; Weatherbee SD; Burgess RW; Ueta R; Yamanashi Y
    Proc Natl Acad Sci U S A; 2014 Nov; 111(46):16556-61. PubMed ID: 25368159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting acetylcholinesterase to the neuromuscular synapse.
    Rotundo RL; Rossi SG; Kimbell LM; Ruiz C; Marrero E
    Chem Biol Interact; 2005 Dec; 157-158():15-21. PubMed ID: 16289417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.